XCR1⁺ cDC1s and Sirpα⁺CD4⁻Esam⁻ cDC2s are minimally affected by manipulation of the LTα₁β₂ pathway. (A) Quantification of splenic XCR1⁺ cDC1s and Sirpα⁺CD4⁻Esam⁻ cDC2s in WT, Rag2^−/−, and Rag2^−/− x γc ^−/− mice treated with the antagonist LTβR-Fc decoy receptor. n = 5 control + 5 LTβR-Fc-treated WT mice, 5 control + 5 LTβR-Fc-treated Rag2^−/− mice, and 8 control + 7 LTβR-Fc-treated Rag2^−/− x γc^−/− mice; two independent experiments per genotype; two-way ANOVA with Sidak’s multiple comparisons post-test. (B) Quantification of splenic XCR1⁺ cDC1s and Sirpα⁺CD4⁻Esam⁻ cDC2s in Rag2^−/− x γc ^−/− mice treated with an agonist LTβR antibody. n = 11 Rag2^−/− x γc ^−/− mice treated with control antibody, and 9 Rag2^−/− x γc^−/− mice treated with anti-LTβR; three independent experiments; Mann–Whitney U test. (C) Quantification of splenic XCR1⁺ cDC1s and Sirpα⁺CD4⁻Esam⁻ cDC2s in Ltb^flox/flox control, Ltb^flox/flox x Cd19-Cre, Ltb^flox/flox x Rorc-Cre, and Ltb^flox/flox x Cd19-Cre x Rorc-Cre mice. n = 11 Ltb^flox/flox control, 15 Ltb^flox/flox x Cd19-Cre, 7 Ltb^flox/flox x Rorc-Cre, and 6 Ltb^flox/flox x Cd19-Cre x Rorc-Cre mice; data verified in at least two independent experiments per genotype; Kruskal–Wallis test with Dunn’s multiple comparisons post-test. (D) Representative flow cytometry plots and quantification of splenic cDCs in uMT^−/− mice treated with the antagonist LTβR-Fc decoy receptor. n = 6 control + 7 LTβR-Fc–treated mice; two independent experiments; two-way ANOVA with Sidak’s multiple comparisons post-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.